Kdo bude hlídat hlídače?

MUDr. Radkin Honzák, CSc.

Urol. praxi. 2016;17(4)  

The use of imaging techniques in urolithiasis

MUDr.Filip Čtvrtlík, Ph.D., MUDr.Zbyněk Tüdös, Ph.D., MUDr.Zuzana Sedláčková, MUDr.Milan Král, Ph.D.

Urol. praxi. 2016;17(4):155-158 | DOI: 10.36290/uro.2016.040  

Urolithiasis is among the most common urological diseases. Given its frequency, manifestations, and complications, it is a serious medical problem. Imaging techniques are of the most benefit in diagnosing lithiasis. In the recent years, CT examination has become the gold standard in investigating urolithiasis, including renal colic.

Immunotherapy for prostate cancer

MUDr.Michal Podrazil, Ph.D., prof.MUDr.Radek Špíšek, Ph.D., prof.MUDr.Jiřina Bartůňková, DrSc.

Urol. praxi. 2016;17(4):159-166 | DOI: 10.36290/uro.2016.041  

Prostate cancer is one of the most common cancers in men. Advances in the field of molecular immunology are leading to a deeper understanding of the interactions between the immune system and cancer, allowing identification of new targets in the immune system and resulting in the development of new anticancer agents. Immunotherapy is emerging as another promising treatment modality in prostate cancer in addition to classic hormonal therapy, radiotherapy and chemotherapy. The aim of this review is to present an overview of current immunotherapeutic approaches, which are being clinically tested in the management of prostate cancer.

Hypospadia

MUDr.Zdeněk Dítě, FEAPU

Urol. praxi. 2016;17(4):167-171 | DOI: 10.36290/uro.2016.042  

Hypospadia is the result of abnormal development of penis characterised by hypoplasia of ventral part of penis. The diagnosis of hypospadia is possible after birth. Moderate forms of hypospadia bring only cosmetic defect, more sever forms are connected with voiding and sexual problems. Severe forms of hypospadia connected with unpalpable gonade could be a manifestation of sexual differentiation disorder and should by widely investigated included genetic screening.

Use of botulinum toxin in the treatment of urinary incontinence

MUDr.Vladimír Šámal, Ph.D., MUDr.Jan Mečl

Urol. praxi. 2016;17(4):172-176 | DOI: 10.36290/uro.2016.043  

Urinary incontinence in patients constitute a major health, psychological and social problem. Botulinum toxin is a substance which blocks the presynaptic release of acetylcholine. When applying to the bladder detrusor muscle leads to its reversible paralysis. Botulinum toxin can be used to treat urinary incontinence due to detrusor overactivity. Currently it is mainlyt used for the treatment of neurogenic detrusor overactivity. The therapeutical effect lasts 6–9 months, continence is restored in up to 80 % of patients. Treatment also has a significant impact on the improvement of urodynamic parameters such as increased cystometric capacity...

The tools assessing health-related quality of life in patients with prostate cancer

MUDr.Ján Švihra jr.

Urol. praxi. 2016;17(4):177-179 | DOI: 10.36290/uro.2016.044  

Recently, a big emphasis is laid not only on treatment of prostate cancer but also on Health-related quality of life of patient (HRQOL). Instruments (questionnaires) assessing HRQOL can be generally-oriented or disease-specific. Making of or translating a questionnaire is a standardized process performed under strict rules of psychometric testing. Characterization and objective evaluation of HRQOL using validated Instruments is useful when deciding about specific-patient-oriented treatment. Authors constantly search the Golden mean – a questionnaire with a number of items as low as possible that describes patient's state in the most...

Komentář ke článku: Nováčková M., Infekce močových cest v těhotenství + Komentář ke článku: Nováčková M., Infekce močových cest v těhotenství

Urol. praxi. 2016;17(4):121-123  

Our experience with testicular adrenal rest tumours in a patient with congenital adrenal hyperplasia

MUDr.Miroslava Ryšánková, MUDr.Pavel Navrátil, MUDr.Ivo Novák, Ph.D., MUDr.Miroslav Podhola, MUDr.Tomáš Kvasnička, doc.MUDr.Miloš Broďák, Ph.D.

Urol. praxi. 2016;17(4):184-186 | DOI: 10.36290/uro.2016.046  

The authors describe a case of a patient diagnosed with bilaterally testicular tumors. This was a patient with congenital adrenal insufficiency and long-term substitution treatment. The correct premise of the patient´s disease led to the preservation of his testicles despite a suspected tumor.

Primary retroperitoneal tumours

MUDr.Eva Poláčková, MUDr.Karel Zita, MUDr.Osvald Cerman

Urol. praxi. 2016;17(4):187-189 | DOI: 10.36290/uro.2016.047  

In our presentation we deal with cases of two patients with primary retroperitoneal tumour – 40 years old man with a malignant type of tumour and 66 years old woman with benign type of retroperitoneal tumour. The content of the article is the symptomatology, diagnosis and therapy of the disease.

Nová technika zlepšující kontinenci po roboticky asistované radikální prostatektomii

Urol. praxi. 2016;17(4):190  

A "problematic" patient at the urologist's surgery

MUDr.Dana Kamarádová, Ph.D., prof.MUDr.Klára Látalová, Ph.D., MUDr.Miroslav Hajda

Urol. praxi. 2016;17(4):180-182  

The treatment of so-called problematic patients is arduous, requiring increased effort and time of the attending staff. A number of various factors, including not only psychological factors, but currently more increasingly socioeconomic ones, can be responsible for the patient’s becoming problematic. Correct treatment of these patients requires a good understanding of the individual factors and the establishing of a good-quality therapeutic relationship. It is sometimes difficult to avoid personal antipathy in treating these patients; nevertheless, even appropriate communicative skills with a problematic patient should be a part of a...

Spomienka na prof. MUDr. Michala Horňáka, DrSc.

Dalibor Ondruš

Urol. praxi. 2016;17(4):197-198  

Effects of a hexane extract of saw palmetto (Serenoa repens, Permixon® 160 mg, available as Capistan® in

MUDr.Lucie Vávřová

Urol. praxi. 2016;17(4):192-194  

Czech Republic) on inflammatory biomarkers in treating symptoms associated with benign prostatic hyperplasia Chronic prostatic inflammation (CPI) can cause symptomatic or complicated benign prostatic hyperplasia (BPH). Based on available data, Capistan, a hexane extract of Serenoa repens (HESr), has anti-inflammatory properties. The aim of the present study was to provide a new insight into the anti-inflammatory effects of HESr by investigating the effect on CPI biomarkers in men with lower urinary tract symptoms (LUTS) due to BPH, while using non-invasive methods and exploring the association between the level of biomarkers and clinical symptoms.